Revance Therapeutics, Inc. (RVNC)
NASDAQ: RVNC · Real-Time Price · USD
5.29
+0.01 (0.19%)
At close: Oct 22, 2024, 4:00 PM
5.39
+0.10 (1.89%)
After-hours: Oct 22, 2024, 5:02 PM EDT
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for RVNC stock have an average target of 10.86, with a low estimate of 6.00 and a high estimate of 20. The average target predicts an increase of 105.29% from the current stock price of 5.29.
Analyst Consensus: Buy
* Price targets were last updated on Sep 13, 2024.
Analyst Ratings
The average analyst rating for RVNC stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 4 | 4 | 4 | 7 | 7 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 12 | 11 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy → Hold Downgrades $10 → $7 | Buy → Hold | Downgrades | $10 → $7 | +32.33% | Sep 13, 2024 |
| Needham | Needham | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 13, 2024 |
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 12, 2024 |
| William Blair | William Blair | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Aug 12, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $11 → $6 | Buy | Maintains | $11 → $6 | +13.42% | Aug 9, 2024 |
Financial Forecast
Revenue This Year
281.68M
from 234.04M
Increased by 20.36%
Revenue Next Year
370.85M
from 281.68M
Increased by 31.66%
EPS This Year
-1.44
from -3.83
EPS Next Year
-0.67
from -1.44
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 296.1M | 424.9M | 573.3M | ||
| Avg | 281.7M | 370.9M | 470.4M | ||
| Low | 261.2M | 312.8M | 365.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 26.5% | 50.9% | 54.6% | ||
| Avg | 20.4% | 31.7% | 26.8% | ||
| Low | 11.6% | 11.1% | -1.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.37 | -0.48 | 0.47 | ||
| Avg | -1.44 | -0.67 | 0.11 | ||
| Low | -1.54 | -0.80 | -0.21 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.